

Autoimmune Disorder

A study of the long-term effects of fenebrutinib treatment in patients with lupus

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Trial Status Terminated	Trial Runs In 11 Countries	Trial Identifier NCT03407482 2017-001764-37 GA30066
-----------------------------------	--------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT03407482 2017-001764-37 GA30066
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 76 Years

Healthy Volunteers
No

This clinical trial was done to study a new medicine called, “fenebrutinib”, for the treatment of patients with “lupus”. Researchers wanted to know if fenebrutinib was safe over a long-term period when given to patients with lupus. One hundred and sixty patients took part in this study at 49 study centers in 11 countries.